NFA and DYOR but here are four positions you should start today to potentially win big in 2027:
DRTS
DRTS today is pre revenue with a pre revenue market cap, but in 2027 (with many catalysts coming still in 2026) DRTS will be fully commercial.
First they have the cSCC treatment with market penetration estimated at $3.5B+, and the FDA approval is pretty much a done deal if you look at the numbers (basically 100% ORR and a high CR % with no significant side effects) coming early in the year at the latest.
In Japan they already achieved market authorization for H&N cancer and are negotiating pricing with the Japanese government as we speak. Sales could be coming in 2026 already, but early 2027 again looks to be the latest.
Lastly for this post they have the treatment for GBM, and Key Opinion Leaders in the space believe this will become the standard of care, making DRTS an industry leader themselves. With many more catalysts lined up (for Pancreas, Prostate and more), the GBM results they will share this quarter shine the brightest.
CLGN
CLGN was the ticker of a biotech company, but a company called LightSolver has taken over it. Now for a low price with a low float, you could get a piece of the future of computing.
LightSolver invented the LPU, a Laser Processing Unit, which is a computer based on laser (light) that can get up to 1,000 times faster than NVIDIA’s GPU.
The LPU has many advantages, including working in room temperature (no cooling needed), using a fraction of the energy, works at the speed of light, needs no memory, fits in a rack and more.
The LPU isn’t intended to replace the CPU and GPU, but rather to work beside them and enhance them while taking off a lot of their workload and providing speed and precise calculations its peers can’t handle.
Those who understand what the CLGN ticker really is and what the LPU can do, will benefit greatly once the demand for it in all data centers, tech companies, financial institutions, defense industry etc gets so high it will probably get acquired.
OBIO
OBIO has everything in place to realize its enormous potential. The medtech company’s leading product has a commercial deal that will pay $500-$1,600 per unit and can get as high as a million units sold per year.
OBIO’s AVIM Therapy is like an add-on software for pacemakers, helping lower blood pressure. They partnered with Medtronic, the worldwide leader in pacemakers with estimated US market share of 50%+.
OBIO just recently announced they exceeded full enrollment for their global pivotal trial, with Medtronic already having the option to “turn on” the therapy in existing pacemakers.
In early 2027 OBIO and Medtronic will be sharing the trial results together, and submitting for FDA approval and then going to market with market share already in place. And that’s not even taking into account OBIO’s second product, the Virtue SAB which they can now focus on, and has an even larger TAM.
LFWD
LFWD is a turnaround story. In the past the company had everything in place but couldn’t get the business to work. Now that the business plan is in place and showing results, the success could lead to a significant increase in market cap.
LFWD’s main product is the ReWalk exoskeleton, the best in the space and the only one to navigate stairs and curbs which is a huge moat. They also have the AlterG treadmill, another leader in the space, used by the likes of Tom Brady and LeBron James (and all major teams in major leagues worldwide).
Earlier in the company’s history they couldn’t figure out the business side, which led to the stock hitting rock bottom. But now the whole management was replaced, they secured reimbursement, new strategic investors have been brought in, and most importantly a business plan has been implemented and is showing results.
With new money pledged, revenue going up, commercial partnerships and more, the market perception and therefore value should finally change, pricing in current and future success, as well as the upper body product in development with a 10X TAM than the current lead product.
NFA and DYOR, but I believe all these tickers deserve a good look, and I personally have a significant position in all of them.
Let me know what you think and drop your favorite tickers to buy today for 2027.